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ABSTRACT _
Use of surrogate measures of effectiveness in cost-effec-
tiveness analyses requires the assumption that a con-
stant and monotonic relationship exists between the
surrogate measure and the clinical outcome of interest.
Results from epidemiologic studies and randomized
controlled trials provide considerable support for the
use of changes in lipids as a surrogate measure of effec-
tiveness for changes in coronary heart disease risk and
mortality in cost-effectiveness analyses of lipid-lowering
therapies. Accordingly, the cost-effectiveness of lipid-
lowering therapies is examined using efficiency-frontier
Results from recent large-scale studies of lipid-lowering therapy in primary and secondary pre-
vention of coronary heart disease (CHD) have estab-
lished that such therapy reduces cardiovascular and
overall mortality [1,2]. Moreover, cost-effectiveness
analyses have demonstrated that lipid-lowering ther-
apy provides good value for money in many patients
[3,4]. A key issue remains, however, concerning
the choice of drug for patients requiring pharma-
cological therapy.
One potential method for assessing which drugs
are most cost-effective is to construct an efficiency
frontier. An efficiency frontier depicts all therapies
that provide the greatest level of effectiveness for a
given cost, or a given level of effectiveness at a min-
imum cost. It is represented graphically by a chart
in which the cost of therapy is displayed along the
x-axis and the measure of effectiveness is displayed
along the y-axis. Cost and effectiveness estimates
for all therapies are plotted on this chart. All thera-
pies with the greatest level of effectiveness at any
given cost are identified. Those so identified consti-
tute the efficiency frontier, which is represented by
a line connecting their coordinates.
To construct an efficiency frontier, it is first nec-
essary to define a measure of effectiveness. From an
outcomes research perspective, an ideal measure of
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analysis and a variety of surrogate measures, including
the percent change in low density lipoprotein cholesterol
(LDL-C) and the ratio of LDL-C to high density lipo-
protein cholesterol (HDL-C), and the percentage of pa-
tients attaining goal LDL-C levels. These analyses sug-
gest that niacin, fluvastatin (20 and 40 mg), simvastatin
(5 mg), pravastatin (20 mg), and atorvastatin (10-80 mg)
are cost-effective therapies; simvastatin (10, 20, and 40
mg), pravastatin (10 and 40 mg), all dosages of lova-
statin, and the bile acid sequestrants are not. Advan-
tages and limitations of this methodology are discussed.
effectiveness would be based on the effects of ther-
apy on clinical outcomes or events. In the case of
lipid-lowering therapy, such measures might include
the incidence of fatal and/or nonfatal CHD, life
expectancy, or quality-adjusted life-years (QALYs).
Unfortunately, use of clinical outcome measures may
not be feasible (or even desirable), and it may be
necessary to use "surrogate measures" of effective-
ness, such as changes in lipid profiles.
Why use surrogate, or efficacy, measures, instead
of clinical outcomes in the evaluation of lipid-lower-
ing therapies? First, evidence of event reduction may
not be available for all therapies, especially new
therapies; such as atorvastatin. Second, while event
studies may have been conducted for some lipid-
lowering therapies, most have compared active ther-
apy to placebo. Because different studies were con-
ducted on different patient populations, estimates of
the effect of therapy on clinical events drawn from
these trials may not be comparable. Third, while
many investigators have modeled the effects of ther-
apy in clinical events based on observed changes in
lipids and estimates of the relationship between lip-
ids and events, there is substantial variability in the
methods and assumptions employed in these investi-
gations. By using surrogate measures of effective-
ness, it is possible to reduce the influence of poten-
tially confounding factors.
A requirement for using a surrogate measure is
that the relationship between it and the clinical
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outcome of interest is both constant (i.e., the same
for all therapies) and monotonic (i.e., positive for all
values of the surrogate measure). Constant means
that the relationship is the same for all therapies.
Monotonic means tha t there is a positive relation-
ship between the measure and the outcome over the
range of interest (i.e., the slope cannot change sign).
Even if the relation ship between the surrogate mea-
sure and the outcome is nonlinear throughout the
range of interest, the conclusions drawn based on
the surrogate measure in terms of the position of
therapies on or off the efficiency frontier still hold,
as long as the relationship is monotonic. Conclu-
sions regarding the incremental cost-effectiveness of
therapies on the frontier may, however, be biased.
For example, if the strength of relationship between
the surrogate measure and the outcome of interest
diminishes as the measure increases, the incremental
cost-effectiveness ratios of therapies with relatively
large effects on the surrogate measure may be un-
derstated.
Th ere is con siderable evidence to support the
assumption that a constant and monotonic rela-
tionship exists between changes in lipids and CHD
risk and mortality. For example, a retrospective ex-
amination of data from the Lipid Research Clinics
Coro nary Primary Prevention Trial (LRC-CPPT) [5]
found a significant positive relationship between
changes in total cholesterol and the magnitude of re-
duction in CHD risk. This relationship was ob-
served with both cholestyrarnine- and placebo-
treated patients parti cipating in the trial. In add i-
tion, the difference in the incidence of CHD events
between the treatment groups was consistent with
reductions in risk predicted by a proportional haz-
ards model that was constructed using the trial data.
Moreover, results of the trial and the model were
consistent with results from other clinical and obser-
vational studies (Fig. 1).
Other support for thi s relat ionship comes from
meta -anal yses of results of randomized, controlled
clinical tr ials. Gould and colleagues [6] performed
a meta-analysis of randomized controlled trials of
a variety of different lipid-lowering therapies in-
cluding diet, drugs, and surgical procedures. This
study was specifically designed to address the rela-
tion ship between reduction in tot al cholesterol
and CHD, non-CHD, and total mortality. The au-
thors found that a 10% reduction in total choles-
terol was associated with a '13-14 % reduction in
CHD mortality and an 8-10% reduction in total
mortalit y. The y found no relation between choles-
terol reduction and non- CHD death. No interven-
tion- specific effects were found among the nonfi -
brare and nonhormone therapies, support ing the
assumption that there is a constant relationship
among these treatment modalities.
A recent meta-analysis performed by Hebert and
colleagues [7] also provides support for the assump-
tion of a positive proport ional relationship between
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lipid reduction and changes in cardiovascular mor-
tality among patients receiving 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) inhibitors, more
commonly known as starins. These authors found
that there were greater reductions in cardiovascular
disease and total mortality in those trials in which
the mean reduction in low density lipoprotein cho-
lesterol (LDL-C) was greater than 30% compared
to those trials in which it was less than 30%.
It should be noted that support for the assump-
tion that the relationship between LDL-C reduc-
tion and CHD risk is linear is more limited. In-
deed, a recent retrospective analysis of data from
the West of Scotland Coronary Prevention Study
(WOSCOPS) suggests that there may be a thresh-
old effect in the relationship between reductions in
LDL-C and coronary events among patients re-
ceiving the HMG-CoA inhibitor pravastatin [8].
Caution should be exercised when interpreting
all the findings cited above, since they are retro-
spective in nature. Also, these studies have not ex-
amined the relationship between cholesterol reduc-
tion and changes in risk of events for all available
statins. Because the range of cholesterol reduction
over which this relationship has been examined has
been limited, the benefits of reduction outside this
range are uncertain. Definitive conclusions must
therefore await additional, preferably comparative
and/or dose-ranging, event studies.
Efficiency-Frontier Analysis of
Lipid-Lowering Therapies
In 1990, Schulman and colleagues [9] used effi-
ciency-frontier analysis to examine the cost-effec-
tiveness of cholestyramine, colestipol, niacin, gem-
fibrozil, probucol, and lovastatin (the only statin
on the market at that time). Effectiveness was ex-
pressed using the percentage reduction in LDL-C
as well as an index of CHD benefit that was based
on changes in both LDL-C and high density lipo-
protein cholesterol (HDL-C). Costs of drugs, phy-
sician visits, lab tests, and treatment of side-effects
were considered. When the costs were graphed
against the percentage reduction in LDL-C, drugs
on the efficiency frontier included niacin, colestipol,
and lovastatin. Drugs that were deemed inefficient
were gernfibrozil, cholestyramine, and probucol.
When the efficiency frontier was constructed using
the reduction in the LDL-CIHDL-C index as the ef-
fectiveness measure, colestipol was displaced from
the frontier by niacin, reflecting the beneficial ef-
fects of niacin on HDL-C. The analysis concluded
that niacin, colestipol, and lovastatin are cost-
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effective therapies and that niacin would dominate
colestipol if the beneficial effects of raising HDL-C
were considered.
Since Schulman performed this analysis, several
additional statins have become available. We re-
cently conducted a similar analysis of all classes of
lipid-lowering drugs deemed important by the Na-
tional Cholesterol Education Program guidelines,
including bile acid sequestrants, niacin, and the
statins. Starins examined included atorvastatin,
fluvastatin, lovastatin, pravastatin, and simvastatin
[10]. A number of different measures of effective-
ness were used including the percentage reduction
in LDL-C and LDL-CIHDL-C ratio, as well as the
percentage of patients attaining goal LDL-C level
(assumed to be 130 mg/dL) for different initial cho-
lesterollevels (assumed to be 160 and 190 mg/dL,
respectively). Estimates of the percentage change in
LDL-C and LDL-CIHDL-C ratio were based on a
meta-analysis of results of randomized controlled
trials. Estimates of the proportion of patients at-
taining goal cholesterol level for each therapy were
calculated using the estimated mean and standard
deviation of the percentage change in LDL-C and
assuming that such changes would be normally dis-
tributed. Costs were limited to those of drugs (based
on average wholesale prices) and lab tests to moni-
tor side-effects. The latter were estimated based on a
variety of published and unpublished data.
When effectiveness was measured in terms of
the percentage change in LDL-C, niacin was found
to be a cost-effective therapy for persons requiring
relatively small reductions in LDL-C (Fig. 2). Also
on the efficiency frontier were fluvastatin (20 and
40 mg), simvastatin (5 mg), pravastatin (20 mg),
and atorvastatin (10-80 mg). Drugs that were off
the efficiency frontier, or "dominated," included
simvastatin (10, 20, and 40 mg), pravastatin (10
and 40 mg), all dosages of lovastatin, and the bile
acid sequestrants (i.e., cholestyramine and colesti-
pol). For therapies on the frontier, the incremental
cost-effectiveness ratios (represented by the inverse
of the slope of the line connecting two points on
the frontier) for simvastatin and pravastatin are
relatively high, while that for atorvastatin is rela-
tively low.
The agents on the efficiency frontier were un-
changed when effectiveness was measured in terms
of the expected percentage of patients attaining goal
LDL-C. The shape of the frontier was different,
however, reflecting changes in the incremental cost-
effectiveness of therapies on the frontier (Fig. 3).
When the change in the LDL-CIHDL-C ratio was
used as the measure of effectiveness, niacin replaced
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Figure 2 Efficiency frontier for lipid-lowering therapies: effectiveness measured using percentage reduction In LDL-C level.
LDL-C, low density lipoprotein cholesterol; N, niacin (2.5 mg); CO, colestipol (4, 10, 15, 16,20 mg); CH. cholestyramine (24 mg);
F. fluvastatin (20, 40 mg); S, simvastatin (5. 10, 20, 40 mg); p. pravastatin (10. 20, 40, 80 mg);A, atorvastatin (10. 20, 40, 80 mg); L,
lovastattn (20. 40, 80 mg).
fluvastarin (20 and 40 mg) on the frontier (Fig. 4).
Arorvastatin was not included in this analysis, since
data needed to calculate this measure were not
available.
Summary and Conclusions
Efficiency-frontier analysis of lipid-lowering therapy
using changes in LDL-C as a surrogate measure of
effectiveness suggests that niacin, fluvastatin (20 and
40 mg), simvastatin (5 mg), pravastatin (20 mg), and
all dosages of arorvasratin are cost-effective thera-
pies; lovastatin and the bile acid sequestrants are
not. However, the incremental cost-effectiveness ra-
tio for sirnvastatin and pravastatin are relatively
high, while that for arorvastatin is relatively low.
Therefore, treatment might be simplified by switch-
ing patients to fluvastatin or atorvastatin, poten-
tially reducing costs without negatively affecting
outcomes.
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Figure 3 Efficiency frontier for lipid.lowering therapies: effectiveness measured using percentage attaining goal LDL-C level.
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Some limitatio ns of this ana lysis should be noted.
First, the costs of alternative therapies were based
on published average who lesale prices. Actua l
costs may vary across settings and over time. The
efficiency front ier may be different, therefore, if
based on prices actua lly paid by providers and/or
pat ients. Second, since this analysis was conducted,
an addi tional sratin has become available (cerivasta-
tin). Inclusion of this therapy might change our find-
ings. Also, as noted above, conclusions regarding
which therapies are on the efficiency frontier rest on
the assumption that there is a constant and mono-
tonic relationship between changes in lipids and re-
duction of the number of clinical events. Conclu-
sions regarding the incrementa l cost-effectiveness of
thera pies on the efficiency frontier require the stron-
ger assumption that the relationship is approxi-
mately linear over the range of interest. While there
is substa ntial evidence to support the former as-
sumption, this evidence is not conclusive. The latter
assumption is more tenuous. Definitive conclusions
must therefore await additional, preferably com-
parat ive, event studies. Until such studies are con-
ducted, providers must make prescribing decisions
by assessing the value of using therapies with
proven beneficial effects on clinical outcomes (e.g.,
pravastarin and simvasratin) versus those without
such strong evidence of clinical benefit (e.g., fluvas-
tarin and atorvas tat in). The value of this proven
benefit must then be weighed against the additional
costs of using the former rather than the latter. Fur-
ther research is required to explore the appropriate
means by which such decisions should be made.
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